Therapeutics Flashcards
SSRI’s mechanism
increase serotonin activity by reducing pre-synaptic reuptake of serotonin after release
…so more serotonin…down regulation of post synaptic receptors
SSRI’s s/e
agitation
nausea
GI disturbance
headache
weight change
sexual dysfunction
suicidal idealation - younger
sertraline safest in
CVD
citalopram s/e
QT prolong
fluoxetine switching
risk of serotonin syndrome
paroxetine stop
discontinuation syndrome
SNRI mechanism
same as SSRI but bind to NA reuptake receptors as well
SNRI s/e
sedation
nausea
sexual dysfunction
mirtazapine mechanism
noradrenergic and specific serotonergic antidepressant - 5HT-2 and 5HT-3 antagonist and H1 activity
mirtazepine
sedation (histamine)
weight gain
TCA uses and examples
if not respond to SSRI’S
newer - lofepramine
older - amitriptyline
TCA s/e
muscarinic and histaminic side effects
QT prolong and arrhythmias
MAOI mechanism
MAOI-A - work on serotonin
MAOI-B - work on dopamine
…both can increase adrenaline
MAOI types
irreversible (more dangerous) - phenelzine, isocarboxazid
reversible (less dangerous) - moclobamide, tranylcypromine
MAOI cautions
potential for significant drug interactions
tyramine reaction leading to hypertensive crisis - avoid cheese, pickled meats, wine and other tyramine products
if changed to another antidepressant, need a washout period (up to 6 weeks)
vortioxetine mechanism
serotonergic activity
vortioxetine s/e
nausea
when use mirtazapine not SSRI
if major weight loss or major sleep difficulty
Anxiety and OCD dose changes
If no initial change, consider increasing
Discontinuation syndrome
Sweating, shakes, agitation, insomnia, headaches, irritability, N+V
…worse if shorter half life (paroxetine and venlafaxine)
Stop paroxetine and venlafaxine
Alternate days of taking or snap in half
Or switch to fluoxetine and then reduce
Serotonin syndrome sx
Headaches, agitation, hypomania, coma, shiver, sweat, hyperthermia, tachycardia, N+V, myoclonus, hyperreflexia, tenor
Serotonin syndrome tx
Fluids and monitor
Antipsychotics mechanism
Reduce levels of dopamine activity at D2 receptors at mesocortical and Mesolimbic pathways
Antipsychotics general s/e
Nigostriatal - movement
Tuberoinfundibular - hypothalamic-pituitary-adrenal axis
Sedation
Extrapyramidal
Weight gain
Acute dystopia - ocuolgyric crisis
Typical v atypical antipsychotics mechanism
Typical - muscarinic and hustaminic receptors
Atypical - serotonergic